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ABSTRACT 
The complement cascade is comprised of a highly sophisticated network of innate immune 
proteins that are activated in response to invading pathogens or tissue injury. The complement 
activation peptide, C5a, binds two seven transmembrane receptors; namely the C5a receptor 1 
(C5aR1) and C5a receptor 2 (C5aR2). C5aR2 is a non-G-protein-signalling receptor whose 
biological role remains controversial. Some of this controversy arises due to the lack of 
selective ligands for C5aR2. In this study, a library of 61 peptides based on the C-terminus of 
C5a was assayed for the ability to selectively modulate C5aR2 function. Two ligands (P32 and 
P59) were identified as functionally selective C5aR2-ligands, exhibiting selective recruitment of 
β-arrestin 2 via C5aR2, partial inhibition of C5a-induced ERK1/2 activation, and LPS-
stimulated IL-6 release from human monocyte-derived macrophages (HMDM). Importantly, 
neither ligand could induce ERK1/2 activation or inhibit C5a-induced ERK1/2 activation via 
C5aR1 directly. Finally, P32 inhibited C5a-mediated neutrophil mobilization in wild-type, but 
not C5aR2-/- mice. These functionally selective ligands for C5aR2 are novel tools that can 
selectively modulate C5a activity in vitro and in vivo, and thus will be valuable tools to 
interrogate C5aR2 function. 
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INTRODUCTION 
The complement cascade is an ancient part of our innate immune system that can be activated 
following tissue injury/damage and in response to foreign bodies 1. Following activation of the 
cascade the complement peptides C3a, C4a and C5a are generated prior to the termination of the 
cascade with the formation of the membrane attack complex 1. C5a is a potent 
immunomodulator, but also has emerging roles outside of immunity during embryonic 
development 23. Its production is tightly controlled in order to produce a rapid response to tissue 
injury/pathogens yet protect against unwanted activity on host tissue 1, 4. The disruption of this 
control can lead to the overproduction of C5a, which can lead to an uncontrolled inflammatory 
response. C5a has been associated with a number of autoimmune, inflammatory and 
neurodegenerative disorders 5, 6 although, interestingly, the overproduction of C5a can lead to a 
down regulation of the immune response in some leukocytes, but have the opposite effect on 
other cell types 7.  
Two receptors have been shown to bind C5a: the C5a receptor 1 (C5aR1 or CD88) and 
the C5a receptor 2 (C5aR2 or C5L2) 8, 9. C5aR1 and C5aR2 are known to have important 
functions in many inflammatory conditions 4. C5aR1 is a classical G protein-coupled receptor 
(GPCR) and activation following C5a binding leads to predominantly Gαi activation which in 
turn activates multiple intracellular signalling pathways (including ERK, Akt, MAPK and 
PI3K) and β-arrestin recruitment for receptor desensitisation, recycling and perhaps also G-
protein independent signalling 1, 4. C5aR2 is a seven transmembrane domain receptor but is not 
coupled to G-proteins, partly due to key amino acid changes in the critical cytosolic DRY and 
NPXXY motifs where G-proteins have been shown to bind 10. However, C5aR2 has been shown 
to bind to β-arrestins 11, 12. C5aR2 was originally thought to be a simple recycling decoy 
receptor, similar to the chemokine receptor D6 13. This assumption is no longer accepted as 
C5aR2 has now been shown to have both pro- and anti-inflammatory activities, and also to have 
its own functional role, which is likely to be regulated through β-arrestin recruitment and 
signalling 14, 15. We have recently published a model that potentially explains the contradictory 
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role of C5aR2 having both pro- and anti-inflammatory activities, through the modulation of C5a 
induced C5aR1 signalling via C5aR2 mediated β−arrestin recruitment 16.  
One inflammatory condition that is strongly associated with the dysregulation of C5a is 
septicaemia 7. The detrimental effects of C5a in sepsis have been well studied and include 
paralysis of neutrophil immune function, promotion of septic cardiomyopathy, driving  the 
apoptosis of adrenal medullar cells and thymocytes, and consumptive coagulopathy which can 
all lead to multi-organ failure 5. Using the caecal ligation and puncture (CLP) model of high 
grade sepsis in mice it was shown that C5aR1 and C5aR2 null animals had an 85% and 80% 
survival rate, respectively at day 3 compared to 0% in normal mice 17. This data suggests that 
there is a cooperative interaction between C5aR1 and C5aR2 during the development of sepsis 
and that blocking of C5a, or both its receptors, could be a very effective therapeutic treatment 
option 18. The pro-inflammatory cytokine IL-6 has been shown to play a key role in septicaemia 
and is involved in regulating the expression of C5aR1 during septicaemia 19.  
The physiological role of C5aR2 however under both pathological and normal conditions 
remains controversial, but it is apparent that it has an important role in C5a biology and 
inflammatory disease 20. A major issue for the field has been lack of selective ligands for C5aR2, 
as current ligands either target C5aR1 alone or interact with both receptors. As such, all of the 
information generated on C5aR2-specific activity to date has been obtained using C5aR2-/- mice, 
C5aR2 genetic knockdown, or C5aR2 blocking antibodies, which each come with their own 
limitations. In order to better understand the contribution of C5aR2 to C5a biology, selective 
ligands for this receptor are required. 
 
 Recently, we designed a library of small peptides based on the C-terminus of C5a 21.  
Surprisingly, none of these peptides induced or inhibited C5aR1 activity, but several were 
instead selective C3aR agonists, giving evidence for the promiscuity of ligands designed to 
target the complement activation peptide receptors. In the current study we further interrogated 
this library for activity at C5aR2 using a radioligand assay to assess binding to C5aR2 
expressing membranes, followed by a bioluminescence resonance energy transfer (BRET) assay 
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to measure β-arrestin 2 recruitment. Two partial agonists were identified that could recruit β-
arrestin 2, selectively inhibit the release of IL-6 and modulate C5a-induced ERK1/2 activation 
in human monocyte-derived macrophages (HMDMs), and inhibit C5a-induced neutrophil 
mobilization in vivo in a C5aR2 dependent manner.  Here we describe the first functionally 
selective C5aR2 ligands, which can recruit β-arrestin 2, selectively inhibit the release of IL-6 
and modulate C5a-induced ERK1/2 activation in HMDMs, and inhibit C5a-induced neutrophil 
mobilization in vivo in a C5aR2-dependent manner. 
 
RESULTS 
Binding of complement proteins to C5aR2 
We initially utilised a Flp-In CHO-C5aR2 membrane preparation to test for the binding activity 
of the anaphylatoxins at C5aR2 using an 125I-C5a displacement scintillation proximity assay 
(SPA). There is still some controversy in the literature as to whether C5aR2 is the receptor for 
C3a-des Arg/acylation-stimulating protein (ASP), with more recent data in the literature that 
suggests this is not the case 22. In our studies, neither C3a nor C3a-des Arg (at concentrations up 
to 1 µM) showed any discernible displacement of 125I-C5a from Flp-In CHO-C5aR2 membrane 
preparations, whilst both C5a and C5a-des Arg displayed full and potent inhibition (Fig. 1). 
This further confirms that C3a and C3a-des Arg (ASP) do not bind to human C5aR2 as has been 
previously reported 23. Furthermore, C5a-des Arg was originally described as a ligand for 
C5aR2 but our data here are in agreement with recent data showing that C5a-des Arg has 
similar affinity/potency as C5a for both C5aR1 and C5aR2 16, 24. This suggests that the 
functional roles of C5a and C5a-des Arg are very similar at C5aR2, and the description of C5a-
des Arg as a predominant ligand for C5aR2 over C5aR1 can no longer be supported. 
 
Screening peptide library for binding to C5aR2 and counter screening hits against C5aR1  
Initially the library was screened at a single concentration of 100 µM for inhibition of 125I-C5a 
binding to C5aR2 membranes. Of the 61 peptides only two peptides (P32, Ac-RHYPYWR-OH, 
and P59, Ac-LIRLWR-OH) showed significant inhibition (P < 0.05) of 125I-C5a binding to 
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C5aR2 membranes when compared to buffer control (Fig. 2A). P32, P59 and P48 (selected as a 
negative control peptide, Ac-TLLRLWR-OH) were than screened using a full concentration 
response up to a maximum concentration of 500 µM (maximum concentration achievable due to 
level of DMSO in assay). Both P32 and P59 dose-dependently inhibited 125I-C5a binding to 
C5aR2 and C5aR1 membranes with Ki in the µM range, whilst P48 only inhibited 
125I-C5a 
binding to C5aR1 (Fig. 2B, C and Table I). P32 had a similar affinity for both C5aR2 (223 µM) 
and C5aR1 (234 µM) whereas P59 had ~10 fold higher affinity for C5aR2 (48 µM) over C5aR1 
(466 µM). P32 and P59 were previously shown to have no activity (either as an agonist or 
antagonist) up to a concentration of 100 µM, when the library was previously screened for 
activity at C3aR and C5aR1 21. 
 
P32 and P59 recruit β-arrestin 2 via C5aR2, but not C5aR1, and are unable to up-regulate 
heteromer formation between C5aR1 and C5aR2 
Due to the non G-protein signalling nature of C5aR2, a BRET C5aR2-β-arrestin 2 recruitment 
assay, previously developed in our lab 16, was used to test peptides for functional activity at 
C5aR2. Both, P32 and P59 were identified as partial agonists for the recruitment of β-arrestin 2 
via C5aR2 (Table 1). Neither ligand could recruit β-arrestin 2 to the same level as C5a, but they 
could recruit β-arrestin 2 at a similar rate to C5a (Fig. 3A). P32 and P59 dose dependently 
recruited β-arrestin 2 via C5aR2 with significantly higher efficacy than their binding affinity for 
C5aR2 (Fig. 3B, Table 1), in contrast to the reduced potency exhibited by C5a. It is now 
accepted that GPCRs act as prototypic allosteric proteins that do not necessarily have a 
stoichiometric relationship between ligand affinity and efficacy with interacting intracellular 
partners 25. Neither, P32 or P59 could recruit β-arrestin 2 via C5aR1 (Fig. 3C), giving further 
evidence for the selectivity of the ligands for C5aR2. In addition, the complete library was 
tested for ligand induced β-arrestin 2 recruitment at C5aR1 and C5aR2 using DiscoverX 
PathHunter kits. Only P32 and P59 showed activity at C5aR2 and no peptide had any activity at 
C5aR1 (data not shown) 26.We have previously shown that high concentrations of C5a can up-
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regulate heteromer formation between C5aR1-C5aR2 27, but neither P32 or P59 were able to up-
regulate heteromer formation between the C5a receptors (Fig. 3D). 
 
P32 and P59 inhibit C5a-induced ERK1/2 activation in HMDM but have no effect on C5a-
induced ERK1/2 activation in CHO-C5aR1 cell line 
It is well known that C5a binding to C5aR1 induces rapid and robust ERK1/2 activation; we 
have recently shown that C5a binding to C5aR2 has no such effect on ERK1/2 activation 16. 
Although C5aR2 has been shown to modulate C5aR1 ERK1/2 activation, this has only been 
tested to date using C5aR2 antibodies 12, 16.  Therefore, P32, P59 and P48 were tested for their 
ability to either directly stimulate ERK1/2 activation, or inhibit C5a-induced ERK1/2 activation 
via C5aR1, in HMDMd and a CHO-C5aR1 cell line (Fig. 4A, B). Neither P32 nor P59 could 
induce ERK1/2 activation alone in either cell type, but both could significantly inhibit C5a-
induced ERK1/2 activation in HMDMs, with no effect in CHO-C5aR1 cells. P48 had no direct 
activity, or effect on C5a-induced ERK1/2 activation, in either cell type. To further confirm that 
P32 and P59 were acting selectively via C5aR2, and not C5aR1, C5a-induced ERK1/2 
activation was quantified in the presence of the potent, selective C5aR1 antagonist, PMX53 28. 
PMX53, unlike P32 and P59, was able to almost completely inhibit ERK1/2 activation in both 
cell types, again further suggesting that P32 and P59 do not exert effects at C5aR1 (Fig. 4A, B 
and Table I). These data support the theory that C5aR2 can modulate C5aR1 induced ERK1/2 
activation most likely through a β-arrestin dependent mechanism, and demonstrates the C5aR2-
functional selectivity of P32 and P59. 
 
P32 and P59 inhibit IL-6 release from HMDM 
It is widely established that C5a receptors are important for the control of LPS-stimulated 
cytokine release from macrophages 29. C5a dose-dependently inhibits the release of the pro-
inflammatory cytokines IL-6 and TNFα, whilst increasing the release of the anti-inflammatory 
cytokine IL-10 from LPS-stimulated HMDMs 30. We thus tested the ability of P32, P59 and P48 
to directly modulate LPS-induced cytokine release from HMDMs. We found that P32 and P59 
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significantly inhibited the release of IL-6 (Fig. 5A), but had no effect on TNFα and IL-10 from 
LPS-stimulated HMDMs (Fig. 5C, E), whereas P48 again had no effect on any of the cytokines 
tested (only IL-6 data shown). Interestingly, both P32 and P59 had a similar maximum level of 
inhibition of IL-6 to C5a. To further demonstrate that P32 and P59 are acting via C5aR2, LPS 
stimulated IL-6 release from HMDMs was quantified in the presence of the C5aR1 antagonist, 
PMX53 (Fig. 5B, D, F). In the presence of PMX53 the effects of C5a on IL-6, TNFα and IL-10 
were completely blocked, whereas the inhibition of IL-6 release by P32 and P59 was unchanged. 
This result gives further evidence for the functional selectivity of P32 and P59 for C5aR2.  
 
P32 inhibits C5a-induced neutrophil mobilization in wild-type, but not C5aR2
-/-
 mice 
Finally, we were interested in assessing whether these C5aR2-selective ligands could be used to 
probe for the role of C5aR2 in vivo. We thus tested the effects of P32 in an acute mouse model 
of C5a-induced neutrophil mobilization. Systemic administration of C5a induces rapid 
neutrophil mobilization (neutrophilia) 31, and C5aR2 is known to affect leukocyte migration and 
adhesion 12, 32. In our hands, intravenous injection of C5a (50 µg/kg) induced a rapid 6-fold 
increase in circulating neutrophils within 30 min (Fig. 6A). When P32 (3 mg/kg i.v.) was 
administered immediately prior to C5a, a significant 50% inhibition of neutrophil mobilization 
was observed (Fig. 6A). Assuming a mouse blood volume of 1.8 mL for a 25g mouse 33, our 
concentration of 3 mg/kg would result in Cmax blood concentrations of ~50 uM, a dose within 
the active range of this compound from our in vitro studies. To confirm this effect of P32 in 
vivo was due to activity at C5aR2, the same experiment was repeated in C5aR2-/- mice. Notably, 
the inhibitory effect of P32 was completely attenuated in C5aR2-/- mice (Fig. 6B), 
demonstrating selectivity of P32 for C5aR2 in vivo at the concentration used. 
 
DISCUSSION 
We have utilised a novel computationally-designed library of 61 hexa-, hepta- and octapeptides 
21 based on the C-terminal sequence of C5a (C-terminal octapeptide sequence = HKDMQLGR-
OH) to discover the first functionally selective agonists for C5aR2 (C5L2/GPR77). 
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Subsequently, we showed that these ligands can recruit β-arrestin 2 via C5aR2, modulate C5a-
induced ERK1/2 activation and specifically inhibit IL-6 release from human macrophages. 
C5aR2 was first thought to be solely a recycling decoy receptor, expressed by cells to remove 
excess C5a from the extracellular fluid, in order to avoid the detrimental C5aR1-mediated 
effects of high C5a concentrations 13. It has now been shown that C5aR2 has additional roles in 
regulating the release of some cytokines and in a number of inflammatory conditions 14, 17, 29 
One of the major impediments to a better understanding of the role of C5aR2 is the dearth of 
selective ligands 20.  
Previously, it has been shown that C5aR2 can recruit and form a complex with β-arrestins, 
which can modulate ERK1/2 signalling in macrophages and neutrophils 12, 16, 34. The simplistic 
view of β-arrestins as only regulators of GPCR desensitisation/internalisation has been updated 
in recent years. β-arrestins are now known to have important signalling roles both independent 
of and in competition with G-protein signalling in addition to their role in GPCR recycling and 
chemotaxis 35. For example, β-arrestin 2 has been shown to act as part of a negative feedback 
loop that regulates the inflammatory response during sepsis 36. With the C5a receptors, IL-6 and 
β-arrestin 2 being shown to be key components in the progression of sepsis 17, 19, 36, the ability to 
now selectively modulate each of these components should further our understanding of this 
difficult to treat condition. Sepsis currently accounts for ~350 000 deaths/year with a mortality 
rate of up to 50% and is responsible for 40% of ICU admissions, costing >$25 billion 
worldwide annually 37. 
The 61-peptide library used in this study was originally designed for binding at C5aR1, 
but we have recently shown the library to contain C3aR-selective agonists with no activity at 
C5aR121. We next decided to test the library for C5aR2 activity due to the similarities between 
C3a and C5a anaphylatoxin receptors. Using a 125I-C5a displacement assay on C5aR2 
expressing membranes, we were able to discover two ligands (P32 and P59) that showed 
significant displacement of 125I-C5a. Follow-up testing showed both ligands to have high 
micromolar affinity for C5aR2 and C5aR1, but more importantly neither displayed any 
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functional activity at C3aR or C5aR1 when previously tested at concentrations up to 100 µM 21. 
Having previously established a BRET C5aR2 β-arrestin 2 recruitment assay 16 the two hit 
peptides were tested for the ability to recruit β-arrestin 2 via C5aR2. Both, P32 and P59 were 
able to recruit β-arrestin 2 with ~37- and 6-fold higher efficacy respectively, than the affinity 
for C5aR2. Even though the peptides had significantly higher efficacy for β-arrestin 2 
recruitment, neither was a full agonist when compared to native C5a. P32 and P59 were also 
both able to inhibit C5a-induced ERK1/2 activation in HMDMs, but had no effect on C5a-
induced ERK1/2 activation in CHO-C5aR1 cells. In addition P32 and P59 could selectively 
inhibit LPS-induced IL-6 release from HMDM even in the presence of PMX53. This data 
suggests that despite the fact that P32 and P59 could inhibit 125I-C5a binding to C5aR1 
membranes, we were unable to identify any functional effect of this binding, giving further 
credence that these ligands are functionally selective for C5aR2. Interestingly, our data also 
demonstrates that C5aR2 can selectively modulate LPS-induced IL-6 release in human 
macrophages, revealing a selective functional role for C5aR2 in inflammatory cytokine 
production. These results are in accord with the reported role for C5aR2 in the regulation of IL-
6 generation from data obtained using C5aR2-/- mice and anti-C5aR2 antibodies 15, 17. 
P32 and P59 both have a C-terminal arginine, which is believed to be a key residue for 
interaction of C5a with the transmembrane region of C5aR2 38. Both peptides replace the 
adjacent glycine residue found in C5a with tryptophan and have a hydrophobic residue (Leu or 
Tyr) at the next position (Leu in C5a), but otherwise differ from C5a. Interestingly, the original 
library of 61 peptides contained some closely related peptides (differing at one or two positions 
from P32 and P59) that did not show significant activity in the original radioligand 
displacement screening assay. In order to begin to establish structure-activity relationships 
(SAR), the ligand displacement Ki and/or β-arrestin 2 recruitment EC50 of these compounds 
could be determined, along with a set of analogues based on the P32/P59 sequences. There is 
precedent for converting peptide ligands of complement receptors into potent small-molecules 39, 
and peptidomimetic approaches could also be investigated. 
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In summary, here we report the discovery of two functionally selective ligands (P32, P59) 
for C5aR2, which are partial agonists (when compared to C5a) for β-arrestin 2 recruitment. 
Importantly, our current and previous 21 data demonstrate that P32 and P59 are devoid of 
activity (either as agonists or antagonists) when screened against C3aR and C5aR1 in a range of 
assays, and can hence be considered as functionally selective ligands for C5aR2. We 
acknowledge that the utility of these ligands will be as tool compounds, rather than direct 
therapeutic candidates, due to their low affinity for C5aR2. Nevertheless these tool ligands 
provide a good starting point to investigate the biological role of C5aR2. This is verified by our 
demonstration that P32 could inhibit C5a-induced neutrophil mobilization in mice, in a C5aR2-
dependent manner. The discovery of these functionally selective C5aR2 ligands will therefore 
now allow complement researchers to selectively probe the functional role of C5aR2 in vitro 
and in vivo. We plan to use these ligands as a medicinal chemistry template for development of 
higher affinity selective ligands for C5aR2. Indeed, the ability of P32 to inhibit C5a-mediated 
ERK1/2 activation and selectively inhibit IL-6 secretion from human macrophages, and block 
C5a-mediated neutrophil mobilization in vivo, indicates that potent and selective C5aR2 
agonists may have therapeutic potential as treatments for inflammatory disease. 
 
 
METHODS 
Materials 
β-arrestin 2-Rluc8 and β-arrestin 2-Venus clones were kindly supplied by Associate Prof. Kevin 
Pfleger (WAIMR, UWA, Perth, Australia). C5aR2 cDNA was supplied by Missouri S&T 
cDNA Resource Center (www.cdna.org). C5aR1-Rluc8 and C5aR2-Venus clones were 
generated previously 27 and kind permission for use of the RLuc8 and Venus constructs was 
provided by Sanjiv Gambhir (Rluc8, Stanford University, CA, USA) and Atsushi Miyawaki 
(Venus, RIKEN Brain Science Institute, Wako-city, Japan). Human recombinant C5a was 
purchased from Sino Biologicals (Beijing, China), human isolated C3a, C3a-des Arg and C5a-
des Arg were purchased from Merck Biosciences (Darmstadt, Germany), recombinant mouse 
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C5a was purchased from Hycult Biotech (Uden, The Netherlands). Glycerol, E. coli-derived 
LPS, BSA, MgCl2, CaCl2, Tris-HCL, DMSO and HEPES were purchased from Sigma-Aldrich 
(St Louis, MO, USA). DMEM, phenol-red free DMEM, IMDM, FBS, streptomycin, penicillin, 
hygromycin B, G418, Ǧ and PBS were purchased from Life Technologies 
(Carlsbad, CA, USA). Recombinant human macrophage-CSF (M-CSF) was purchased from 
Miltenyi Biotec (Macquarie Park, NSW, Australia).  
Design of the peptide library 
The peptide library consisted of 61 octa-, hepta- and hexapeptides designed around the C-
terminal sequence and structure of C5a. A two-stage de novo protein design computational 
framework was used to construct the peptide library, based on flexible structural templates of 
C5a from molecular dynamics simulations, as previously described 21. The full list of sequences 
of the peptide library is in Halai et al, 2014 21. The computational framework, its evolution and 
applications in peptide design are described in 21, 40, 41 
Peptide synthesis 
All initial peptides were synthesized by GenScript (Piscataway, NJ) with acetylated N-termini 
at >95% purity. The C-termini of all peptides was unblocked. Purity was confirmed by 
analytical HPLC. The 61 peptides of the library were dissolved in dimethyl sulfoxide (DMSO) 
at a stock concentration of 10 mM and stored at -20oC till needed for assay. Lead peptides were 
then dissolved in DMSO at a stock concentration of 100 mM. Resyntheses of P32 and P59 were 
conducted by Mimotopes Pty Ltd (Clayton, Vic, Australia) to >95% purity, confirmed by 
analytical HPLC and LCMS analysis. 
 
Cell Culture and transfection  
HEK293 cells were maintained in DMEM containing 10% FBS, 50 IU mL-1 penicillin, 50 mg 
mL-1 streptomycin (Life technologies) at 37 oC and 5% CO2. Flp-In™ CHO cells stably 
expressing human C5aR2 were generated in-house using the Flp-In™ system (Life 
Discovery of functionally selective C5aR2 ligands 
13 
Technologies). The Flp-In™ CHO-C5aR2 were cultured in a buffer of Ham’s F12, 10% FBS, 
50 IU mL-1 penicillin, 50 ȝg mL-1 streptomycin and 1000 ȝg mL-1 hygromycin B (Life 
Technologies). CHO cells stably expressing C5aR1 (Perkin Elmer, Waltham, MA, USA) were 
maintained were cultured in Ham’s F12, 10% FBS, 100 IU mL-1 penicillin, 100 ȝg mL-1 
streptomycin and 400 ȝg mL-1 G418 (Life Technologies). Cells were passaged at 80% 
confluence using 0.05% trypsin: EDTA in phosphate-buffered saline (PBS), pH 7.4. All cells in 
culture, once seeded, were incubated at 37 °C with 5% CO2, unless stated otherwise. Transient 
transfections of HEK cells were performed 24 h after seeding cells at 1 x 106 cells per well in a 
100-mm dish. X-tremeGENE 9 transfection reagent (Roche, Basel, Switzerland) was used 
according to the manufacturer’s instructions. Cells were collected 24 h after transfection with 
0.05% trypsin-EDTA in PBS (Life Technologies). To generate HMDMs, human monocytes 
were isolated from buffy coat blood supplied by unknown donors by the Australian Red Cross 
Blood Service (Kelvin Grove, Australia) using Ficoll-Plaque Plus (GE Healthcare, Rydalmere, 
NSW, Australia) and density centrifugation. CD14+ cell selection was performed using MACS 
magnetic beads (Miltenyi Biotec) 42. Isolated CD14+ monocytes were differentiated in culture 
for 7 days with 10 ng ml-1 human M-CSF (Miltenyi Biotec) into HMDMs in the presence of 
IMDM containing L-glutamine supplemented with 10 % FBS, 50 IU ml-1 penicillin and 50 mg 
ml-1 streptomycin (Life Technologies) 43.  
 
C5aR2/C5aR1 membrane preparation 
Membranes were prepared from Flp-In CHO-C5aR2 and CHO-C5aR1 cells by a previously 
described method 44. Briefly, cells were washed with PBS, pH 7.4, and harvested into buffer (50 
mM Tris-HCl, pH 7.4, 5 mM MgCl2, 1 mM CaCl2) before homogenizing with a Polytron 
homogenizer for 3 min on setting 22. Cells were centrifuged at 150 x g for 5 min at 4 °C. The 
supernatant was recovered and centrifuged at 22 000 x g for 1 h at 4 °C. Membrane pellets were 
then resuspended in 0.4 mL of ice-cold buffer (50 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 1 mM 
CaCl2, containing 10% glycerol) with aliquots stored at í80 °C. The protein concentration of 
the membrane preparation was determined by the Bradford method 45. 
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C5aR2/C5aR1 receptor binding studies 
C5aR2/C5aR1 receptor binding studies were performed using a modification of a previously 
described scintillation proximity assay (SPA) method 46. Briefly, SPA studies were performed 
in 96-well white isoplates with clear flat bottoms (Perkin Elmer). SPA beads (200 µg/well) were 
added, following the addition of various concentrations of competing ligands or buffer (6 pM to 
500 µM) in a total volume of 80 µL of assay buffer (50 mM Tris-HCl, pH 7.4, 0.5% BSA, 5 
mM MgCl2, 1 mM CaCl2). 
125I-C5a (~20 pM) (specific activity, 2200 Ci mmol-1) (Perkin Elmer) 
was added to membrane preparations (~2 µg/well). The final reaction volume per well 
comprised 20 µL of ligand/buffer, 20 µL of SPA beads, 20 µl of membrane and the assay was 
initiated by the addition of 20 µL of 125I-C5a. The plate was then sealed using TopSeal-A 
(Perkin Elmer) sealing film and incubated with shaking for 1 h at room temperature. 
Radioligand binding was then assessed for 30 s/well using a 1450 Microbeta scintillation 
counter (Perkin Elmer).  
 
BRET assays for recruitment of β-arrestin 2 to C5a receptors and between C5a receptors 
Assays were performed as a ligand-induced BRET experiment similar to previously described 16, 
27, 47. In brief, HEK293 cells were transiently transfected with either C5aR1-Rluc8 and β-
arrestin 2-Venus or C5aR2-Venus and β-arrestin 2-Rluc8 or C5aR1-Rluc8 and C5aR2-Venus in 
a 100-mm dish. 24 h after transfection cells were collected and transferred to a 96-well white 
microplate (Corning, NY, USA) in phenol-red free DMEM containing 5% FBS and 25 mM 
HEPES (Life Technologies). Cells were allowed to settle for 24 h and then were incubated with 
30 µM Enduren (Promega, Madison, WI, USA) for 2 h at 37 oC and 5% CO2 to ensure that the 
substrate had reached equilibrium. Following incubation BRET baseline measurements were 
taken for 15 min then ligands were added to plate and BRET measurements were taken for a 
further 1 h at 37 oC using a M1000Pro plate reader (Tecan, Männedorf, Switzerland). Filtered 
light emissions were sequentially measured for 1 s in each of the following windows 460–490 
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nm and 520–550 nm, both before and following ligand addition. The ligand-induced BRET 
ratio was calculated by subtracting the ratio of 520–550 nm emission over the 460–490 nm 
emission for a vehicle-treated sample from a ligand-treated sample of the same aliquot of cells 
in triplicate. The BRET ratio was calculated by subtracting the ratio of 520–550 nm emission 
over the 460–490 nm emission for a cell sample containing the C5aR1-Rluc8 or β-arrestin 2-
Rluc8 construct from a cell sample containing both the C5aR1-Rluc8 and β-arrestin 2-Venus or 
C5aR2-Venus and β-arrestin 2-Rluc8 or C5aR1-Rluc8 and C5aR2-Venus constructs. Peptides 
were also tested for ligand-induced β-arrestin 2 recruitment at 100µM using DiscoveRx 
PathHunter kits for human C5aR1 and C5aR2 (DiscoveRx Corporation, Birmingham, UK), 
according to the manufacturer’s instructions. 
 
ERK1/2 Phosphorylation Assays 
ERK1/2 phosphorylation assays were performed using the Alphascreen Surefire ERK1/2 kit 
(Perkin Elmer) as per manufacturers’ instructions and previously described 44. Briefly, HMDMs 
or CHO-C5aR1 cells were seeded at 50 000 cells/well in 96-well tissue culture plates (Nunc, 
Waltham, MA, USA) and serum starved overnight. Ligands were prepared in serum-free media. 
C5aR2 ligands were pre-incubated with cells for 30 min at 37 °C and 5% CO2, prior to the 
addition of C5a (5 nM) for 10 min at 37 °C and 5% CO2. Media was then removed and cells 
lysed with lysis buffer for 10 min on a shaker, 4 ȝL of lysate was transferred to a white 384-
well proxiplate plate (Perkin Elmer) and incubated in the presence of 7 ȝL of reaction mix. The 
plate was sealed with TopSeal-A, incubated for 2 h at 37 °C and measured on an M1000Pro 
plate reader (Tecan). 
 
Measurement of cytokine release from HMDM 
Briefly, HMDMs were seeded in 96 well tissue culture plates (Nunc) at 100 000 cells/well and 
allowed to adhere overnight at 37 °C and 5% CO2. The next day HMDMs were stimulated with 
E.coli derived LPS (10 ng ml-1) only or LPS (10 ng ml-1) and either C5a or C5aR2 ligands at 
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various concentrations (1-100 nM (C5a) or 0.1-100 µM (C5aR2 ligands)). For testing cytokine 
release in the presence of C5aR1 antagonist (PMX53), cells were pre-incubated with PMX53 
(10 µM) for 30 min prior to addition of C5a or C5aR2 ligands. Following ligand addition 
HMDMs were returned to 37 °C and 5% CO2 incubator and 24 h after stimulation supernatant 
was removed from cells and transferred to 96 well polypropylene microplate (Nunc) and stored 
at -20 oC till needed for assay. Quantification of cytokine release was performed using ELISA 
kits (BD OptEIA™) as per manufacturers’ instructions (BD Biosciences, San Jose, CA, USA). 
 
Neutrophil mobilization experimental design 
The University of Queensland Animal Ethics Committee approved all mouse experiments. 
C57BL/6J wild-type mice or C5L2-/- mice on a C57BL/6J background were given the vehicle 
(sterile saline) or C5L2 agonist (P32) (3 mg/kg) intravenously into the femoral vein. Following 
this injection a further intravenous injection of either vehicle (sterile saline) or recombinant 
mouse C5a (50 µg/kg) was administered to the opposite femoral vein. After 30 minutes blood 
samples (collected in 1 mg/mL EDTA and 0.1 mg/mL FUT-175) were collected from the 
abdominal aorta. Total circulating leukocyte counts were determined from blood smears and 
total white blood cell counts using a hemocytometer.  
 
Data and statistical analysis 
The Graphpad Prism version 6 software was used for all statistical and graphical analysis 
(Graphpad Software, La Jolla, CA, USA). Sigmoidal curves were fitted to the dose-response 
curves using non-linear regression. Data from at least three separate experiments are expressed 
as mean, and error bars represent SEM. Statistical analysis was performed using a one-way 
ANOVA with Dunnett’s or Sidak’s correction, for multiple comparisons, differences were 
considered significant if P < 0.05. 
 
ACKNOWLEDGEMENTS 
We would like to acknowledge The Australian Red Cross for their supply of buffy coat tested 
Discovery of functionally selective C5aR2 ligands 
17 
blood for these studies. We thank Dr. Ruth Seeber and Associate Prof. Kevin Pfleger for the 
supply of the β-arrestin BRET clones and their helpful advice in the development of the BRET 
assays. The authors wish to declare no conflicts of interest. 
 
AUTHORSHIP CONTRIBUTIONS 
Daniel Croker proposed, designed, performed and analyzed the experiments. Peter Monk 
proposed, designed, performed and analyzed experiments. Reena Halai contributed to the design 
of the experiments and data analysis. Geraldine Kaeslin, Zoe Schofield and Mike Wu designed 
and performed experiments. Dimitrios Morikis, Christodoulos Floudas contributed the design of 
the peptide library. Richard Clark, Mark Blaskovich analysed data and arranged peptide 
resynthesis. Matthew Cooper contributed to the design of the experiments and obtained funding 
for the research. Trent Woodruff proposed, designed, performed and analysed experiments. All 
authors participated in writing the manuscript. 
 
  
Discovery of functionally selective C5aR2 ligands 
18 
REFERENCES 
1. Klos A, Wende E, Wareham KJ, Monk PN. International Union of Pharmacology. 
LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors. Pharmacological 
Reviews 2013; 65(1): 500-543. 
 
2. Denny KJ, Coulthard LG, Jeanes A, Lisgo S, Simmons DG, Callaway LK et al. C5a 
receptor signaling prevents folate deficiency-induced neural tube defects in mice. J 
Immunol 2013; 190(7): 3493-9. 
 
3. Hawksworth OA, Coulthard LG, Taylor SM, Wolvetang EJ, Woodruff TM. Brief 
report: complement C5a promotes human embryonic stem cell pluripotency in the 
absence of FGF2. Stem Cells 2014; 32(12): 3278-84. 
 
4. Monk PN, Scola AM, Madala P, Fairlie DP. Function, structure and therapeutic 
potential of complement C5a receptors. Br J Pharmacol 2007; 152(4): 429-448. 
 
5. Klos A, Tenner AJ, Johswich K-O, Ager RR, Reis ES, Köhl J. The role of the 
anaphylatoxins in health and disease. Mol Immunol 2009; 46(14): 2753-2766. 
 
6. Woodruff TM, Ager RR, Tenner AJ, Noakes PG, Taylor SM. The role of the 
complement system and the activation fragment C5a in the central nervous system. 
Neuromolecular Med 2010; 12(2): 179-92. 
 
7. Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol 2004; 4(2): 133-142. 
 
Discovery of functionally selective C5aR2 ligands 
19 
8. Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 
1991; 349: 614-617. 
 
9. Cain SA, Monk PN. The Orphan Receptor C5L2 Has High Affinity Binding Sites for 
Complement Fragments C5a and C5a des-Arg74. J Biol Chem 2002; 277(9): 7165-7169. 
 
10. Okinaga S, Slattery D, Humbles A, Zsengeller Z, Morteau O, Kinrade MB et al. C5L2, 
a nonsignaling C5A binding protein. Biochemistry 2003; 42(31): 9406-15. 
 
11. Van Lith LH, Oosterom J, Van Elsas A, Zaman GJ. C5a-stimulated recruitment of ȕ-
arrestin2 to the nonsignaling 7-transmembrane decoy receptor C5L2. J Biomol Screen 
2009; 14(9): 1067-75. 
 
12. Bamberg CE, Mackay CR, Lee H, Zahra D, Jackson J, Lim YS et al. The C5a receptor 
(C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem 2010; 
285(10): 7633-44. 
 
13. Scola AM, Johswich KO, Morgan BP, Klos A, Monk PN. The human complement 
fragment receptor, C5L2, is a recycling decoy receptor. Mol Immunol 2009; 46(6): 
1149-62. 
 
14. Chen N-J, Mirtsos C, Suh D, Lu Y-C, Lin W-J, McKerlie C et al. C5L2 is critical for 
the biological activities of the anaphylatoxins C5a and C3a. Nature 2007; 446(7132): 
203-207. 
 
Discovery of functionally selective C5aR2 ligands 
20 
15. Gao H, Neff TA, Guo RF, Speyer CL, Sarma JV, Tomlins S et al. Evidence for a 
functional role of the second C5a receptor C5L2. FASEB J 2005; 19(8): 1003-5. 
 
16. Croker DE, Halai R, Kaeslin G, Wende E, Fehlhaber B, Klos A et al. C5a2 can 
modulate ERK1/2 signaling in macrophages via heteromer formation with C5a1 and 
beta-arrestin recruitment. Immunol Cell Biol 2014; 92: 631-639. 
 
17. Rittirsch D, Flierl MA, Nadeau BA, Day DE, Huber-Lang M, Mackay CR et al. 
Functional roles for C5a receptors in sepsis. Nat Med 2008; 14(5): 551-7. 
 
18. Ward PA, Guo RF, Riedemann NC. Manipulation of the complement system for benefit 
in sepsis. Crit Care Res Pract 2012; 2012: 1-8. 
 
19. Riedemann NC, Neff TA, Guo RF, Bernacki KD, Laudes IJ, Sarma JV et al. Protective 
Effects of IL-6 Blockade in Sepsis Are Linked to Reduced C5a Receptor Expression. J 
Immunol 2003; 170(1): 503-507. 
 
20. Li R, Coulthard LG, Wu MC, Taylor SM, Woodruff TM. C5L2: a controversial 
receptor of complement anaphylatoxin, C5a. FASEB J 2013; 27(3): 855-64. 
 
21. Halai R, Bellows-Peterson ML, Branchett W, Smadbeck J, Kieslich CA, Croker DE et 
al. Derivation of ligands for the complement C3a receptor from the C-terminus of C5a. 
Eur J Pharmacol 2014; 745: 176-81. 
 
Discovery of functionally selective C5aR2 ligands 
21 
22. Johswich K, Klos A. C5L2--an anti-inflammatory molecule or a receptor for acylation 
stimulating protein (C3a-desArg)? Adv Exp Med Biol 2007; 598: 159-80. 
 
23. Johswich K, Martin M, Thalmann J, Rheinheimer C, Monk PN, Klos A. Ligand 
Specificity of the Anaphylatoxin C5L2 Receptor and Its Regulation on Myeloid and 
Epithelial Cell Lines. J Biol Chem 2006; 281(51): 39088-39095. 
 
24. Reis ES, Chen H, Sfyroera G, Monk PN, Kohl J, Ricklin D et al. C5a receptor-
dependent cell activation by physiological concentrations of desarginated C5a: insights 
from a novel label-free cellular assay. J Immunol 2012; 189(10): 4797-805. 
 
25. Kenakin T. Collateral efficacy in drug discovery: taking advantage of the good 
(allosteric) nature of 7TM receptors. Trends Pharmacol Sci 2007; 28(8): 407-15. 
 
26. Monk PN, Bellows-Peterson ML, Smadbeck J, Floudas CA, Kieslich CA, Morikis D et 
al. De novo protein design of agonists and antagonists of C5a receptors. Immunobiology 
2012; 217(11): 1162-1163. 
 
27. Croker DE, Halai R, Fairlie DP, Cooper MA. C5a, but not C5a-des Arg, induces 
upregulation of heteromer formation between complement C5a receptors C5aR and 
C5L2. Immunol Cell Biol 2013; 91: 625-633. 
 
28. Woodruff TM, Nandakumar KS, Tedesco F. Inhibiting the C5-C5a receptor axis. Mol 
Immunol 2011; 48(14): 1631-42. 
 
Discovery of functionally selective C5aR2 ligands 
22 
29. Bosmann M, Haggadone MD, Zetoune FS, Sarma JV, Ward PA. The interaction 
between C5a and both C5aR and C5L2 receptors is required for production of G-CSF 
during acute inflammation. Eur J Immunol 2013; 43(7): 1907-13. 
 
30. Seow V, Lim J, Iyer A, Suen JY, Ariffin JK, Hohenhaus DM et al. Inflammatory 
responses induced by lipopolysaccharide are amplified in primary human monocytes 
but suppressed in macrophages by complement protein C5a. J Immunol 2013; 191(8): 
4308-16. 
 
31. Jagels MA, Hugli TE. Neutrophil chemotactic factors promote leukocytosis. A common 
mechanism for cellular recruitment from bone marrow. J Immunol 1992; 148(4): 1119-
28. 
 
32. Pundir P, MacDonald CA, Kulka M. The Novel Receptor C5aR2 Is Required for C5a-
Mediated Human Mast Cell Adhesion, Migration, and Proinflammatory Mediator 
Production. J Immunol 2015; 195(6): 2774-87. 
 
33. Diehl KH, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D et al. A good 
practice guide to the administration of substances and removal of blood, including 
routes and volumes. J Appl Toxicol : JAT 2001; 21(1): 15-23. 
 
34. Hsu WC, Yang FC, Lin CH, Hsieh SL, Chen NJ. C5L2 is required for C5a-triggered 
receptor internalization and ERK signaling. Cell Signal 2014; 26(7): 1409-19. 
 
Discovery of functionally selective C5aR2 ligands 
23 
35. Defea K. Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in 
signal transduction. Br J Pharmacol 2008; 153 Suppl 1: S298-309. 
 
36. Fan H, Bitto A, Zingarelli B, Luttrell LM, Borg K, Halushka PV et al. Beta-arrestin 2 
negatively regulates sepsis-induced inflammation. Immunology 2010; 130(3): 344-51. 
 
37. Schorr CA, Dellinger RP. The Surviving Sepsis Campaign: past, present and future. 
Trends Mol Med 2014; 20(4): 192-4. 
 
38. Scola AM, Higginbottom A, Partridge LJ, Reid RC, Woodruff T, Taylor SM et al. The 
role of the N-terminal domain of the complement fragment receptor C5L2 in ligand 
binding. J Biol Chem 2007; 282(6): 3664-71. 
 
39. Reid RC, Yau MK, Singh R, Hamidon JK, Reed AN, Chu P et al. Downsizing a human 
inflammatory protein to a small molecule with equal potency and functionality. Nature 
Commun 2013; 4: 2802. 
 
40. Bellows-Peterson ML, Fung HK, Floudas CA, Kieslich CA, Zhang L, Morikis D et al. 
De novo peptide design with C3a receptor agonist and antagonist activities: theoretical 
predictions and experimental validation. J Med Chem 2012; 55(9): 4159-68. 
 
41. Klepeis JL, Floudas CA, Morikis D, Tsokos CG, Argyropoulos E, Spruce L et al. 
Integrated Computational and Experimental Approach for Lead Optimization and 
Design of Compstatin Variants with Improved Activity. J Am Chem Soc 2003; 125: 
8422-8423. 
Discovery of functionally selective C5aR2 ligands 
24 
 
42. Verreck FAW, Boer Td, Langenberg DML, Hoeve MA, Kramer M, Vaisberg E et al. 
Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 
macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A 2004; 
101(13): 4560-4565. 
 
43. Halili MA, Andrews MR, Labzin LI, Schroder K, Matthias G, Cao C et al. Differential 
effects of selective HDAC inhibitors on macrophage inflammatory responses to the 
Toll-like receptor 4 agonist LPS. J Leukoc Biol 2010; 87(6): 1103-14. 
 
44. Halai R, Croker DE, Suen JY, Fairlie DP, Cooper MA. A Comparative Study of 
Impedance versus Optical Label-Free Systems Relative to Labelled Assays in a 
Predominantly Gi Coupled GPCR (C5aR) Signalling. Biosensors 2012; 2(3): 273-290. 
 
45. Bradford MM. A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 
72: 248-54. 
 
46. Dutertre S, Croker D, Daly NL, Andersson A, Muttenthaler M, Lumsden NG et al. 
Conopressin-T from Conus tulipa reveals an antagonist switch in vasopressin-like 
peptides. J Biol Chem 2008; 283(11): 7100-8. 
 
47. Kocan M, Dalrymple MB, Seeber RM, Feldman BJ, Pfleger KD. Enhanced BRET 
Technology for the Monitoring of Agonist-Induced and Agonist-Independent 
Interactions between GPCRs and ȕ-Arrestins. Front Endocrinol 2011; 1: 12. 
Discovery of functionally selective C5aR2 ligands 
25 
 
FIGURE LEGENDS 
Figure 1: C5aR2 binding affinity for the complement proteins C3a, C3a-des Arg, C5a and 
C5a-des Arg. Binding affinities for complement proteins: C5a Ki = 1.3 s0.3 nM, C5a-des Arg 
Ki = 1.5 s0.4 nM, C3a and C3a-des Arg Ki > 1 µM. Data is representative of at least three 
independent experiments performed in triplicate (n = 3-5). Data is normalised to C5a response 
for each experiment. Error bars represent SEM. 
 
Figure 2: Identification and verification of hits at C5aR2 from 61-peptide library. (A) 
Testing of 61-peptide library at 100 µM for inhibition of 125I-C5a binding to C5aR2 membranes. 
Asterisks indicate hits that show significant (P < 0.05) inhibition of 125I-C5a binding compared 
to buffer control. (B) Sigmoidal dose-response curves for the hits P32, P59 and negative control 
peptide P48 for inhibition of 125I-C5a binding to C5aR2 membranes. (C) Sigmoidal dose-
response curves for the significant hits P32, P59 and negative control peptide P48 for inhibition 
of 125I-C5a binding to C5aR1 membranes. Data is normalised to C5a response for each 
experiment. Data (mean ± SEM) are representative of at least three independent experiments 
performed in triplicate (n = 3-4). Error bars represent SEM; *P < 0.05 by one-way ANOVA 
followed by Dunnett’s post hoc test. 
 
Figure 3: BRET assay testing hits for β-arrestin 2 recruitment by C5aR1 or C5aR2 and 
ligand induced heteromer formation between C5a receptors. (A) Ligand-induced BRET 
ratio for β-arrestin 2 recruitment by C5aR2 for C5a (500 nM), P32 or P59 (100 µM). (B) 
Sigmoidal dose response curves for C5a, P32 or P59 for β-arrestin 2 recruitment by C5aR2 
calculated at ~40 min after ligand addition. (C) Ligand-induced BRET ratio for β-arrestin 2 
recruitment by C5aR1 for C5a (500 nM), P32 or P59 (100 µM). (D) Ligand-induced BRET 
ratio for up-regulation of heteromer formation between C5aR1-C5aR2 for C5a (500 nM), P32 
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or P59 (100 µM). Data (mean ± SEM) are representative of at least three independent 
experiments performed in triplicate (n = 3-4). 
 
Figure 4: P32 and P59 inhibit C5a-induced ERK1/2 activation in HMDM but have no 
effect on CHO-C5aR1 ERK1/2 activation. (A) Measurement of pERK1/2 activation in 
HMDM: HMDM were pre-incubated with media, C5aR1 antagonist PMX53 (10 µM), P32, P48 
or P59 (100 µM) for 30 min prior to stimulation with media control (buffer), C5a (5 nM), 
PMX53 (10 µM), P32, P48 or P59 (100 µM) for 10 min. Data is normalised to C5a 5 nM 
(100%) for each donor. (B) Measurement of pERK1/2 activation in CHO-C5aR1: cells were 
pre-incubated with media, PMX53 (10 µM), P32, P48 or P59 (100 µM) for 30 min prior to 
stimulation with media control (buffer), C5a (5 nM), PMX53 (10 µM), P32, P48 or P59 (100 
µM) for 10 min. Data is normalised to C5a 5 nM (100%) for each experiment. Data (mean ± 
SEM) are representative of at least four independent HMDM donors or CHO-C5aR1 
experiments performed in triplicate (n = 4-8); **** P < 0.0001 by one-way ANOVA followed 
by Dunnett’s post hoc test. 
 
Figure 5: Testing P32 and P59 for effects on cytokine release from LPS stimulated HMDM. 
Measurement of human inflammatory cytokines IL-6 (A, B), TNFα (C, D) and IL-10 (E, F) 
release from HMDM, 24 h after co-stimulation with LPS (10 ngml-1) and C5a (0.1-100 nM), 
P32, P48 or P59 (0.1-100 µM) with or without C5aR1 antagonist PMX53 (10 µM) present. 
Cytokine release quantified by ELISA. CTRL represents non-stimulated HMDM. Data is 
normalised to LPS response (100%) for each donor. Data (mean ± SEM) are representative of at 
least five independent HMDM donors performed in triplicate (n = 5-8); *P < 0.05, ** P < 0.01, 
*** P < 0.001, **** P < 0.0001 by one-way ANOVA followed by Dunnett’s post hoc test or 
Sidak’s post hoc test for comparisons +/- PMX53. 
 
Figure 6: P32 inhibits C5a-induced neutrophil mobilization in vivo in a C5aR2 dependent 
manner.  Blood neutrophil counts quantified 30 min after i.v. injection of PBS, C5a (50 µg/kg), 
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P32 (3 mg/kg), or P32 (3 mg/kg) with and without C5a (50 µg/kg) in either wild-type (A) or 
C5aR2-/- (B) mice. Data (mean ± SEM) represent 4-6 mice per treatment group; * P < 0.05, *** 
P < 0.001 by one-way ANOVA followed by Sidak’s post hoc test. 
 
 
 






TABLES 
Table I: Binding affinity and efficacy for ligands at C5aR2 and C5aR1 
 Sequence C5aR2 
binding 
C5aR2-β-arrestin 2 
BRET 
C5aR1 
binding 
C5aR1 pERK1/2 
  Ki 
± SEM 
EC50 
± SEM 
Recruitment 
(% of C5a) 
Ki 
± SEM 
% Inhibition 
of C5a 5 nM 
C5a  1.8 ± 
0.3 nM 
53.7 ± 
5.2 nM 
100 0.57 ± 
0.08 nM 
PMX53 
90 
P32 RHYPYWR 223 ± 
140 µM 
5.2 ± 
0.9 µM 
28.8 234 ± 
230 µM 
8 
P59 LIRLWR 64 ± 23 
µM 
6.4 ± 
0.5 µM 
52.9 466 ± 
59 µM 
7 
 
